{"id":335267,"date":"2026-11-02T18:07:03","date_gmt":"2026-11-02T12:37:03","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/akums-drugs-and-pharmaceuticals-q2-results-fy27-pat-115-crore\/"},"modified":"2026-11-02T18:07:03","modified_gmt":"2026-11-02T12:37:03","slug":"akums-drugs-and-pharmaceuticals-q2-results-fy27-pat-115-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/akums-drugs-and-pharmaceuticals-q2-results-fy27-pat-115-crore\/","title":{"rendered":"Akums Drugs & Pharmaceuticals Q2 Results FY27: Revenue Up 31.93% to Rs 1,342.39 Cr, PAT Up 168.31% to Rs 114.57 Cr"},"content":{"rendered":"
\n

Quick Answer<\/strong><\/p>\n

Akums Drugs & Pharmaceuticals Q2 Results FY27 were declared on 2 November 2026. Consolidated revenue reached Rs 1,342.39 Cr, up 31.93% from Rs 1,017.53 Cr a year earlier, while net profit rose 168.31% to Rs 114.57 Cr from Rs 42.70 Cr. Operating Profit was Rs 194.73 Cr. These quarterly results show YoY growth across all three lines.<\/p>\n<\/div>\n

Akums Drugs & Pharmaceuticals Ltd<\/a> (AKUMS) Q2 Results FY27 announced on 2 November 2026, covering the company’s financial performance for the July to September quarter. The Consolidated figures show revenue of Rs 1,342.39 Cr and PAT of Rs 114.57 Cr. With the results date now on record, Akums Drugs & Pharmaceuticals Q2 Results FY27 give investors a full set of comparable numbers from NSE and BSE filings, and the consolidated results show higher revenue and profit.<\/p>\n

This results analysis of Akums Drugs & Pharmaceuticals Q2 Results walks through the financial highlights, business drivers, outlook and risks behind the headline figures. Univest presents the numbers in the sequence most readers follow, beginning with the Financial Highlights table placed directly below.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n